Potential Natural Dual Agonist PPARα/γ-induced Antidiabetic and Antidyslipidemic Properties of Safrole-Free Nutmeg Seed (Myristica fragrans Houtt) Extract

Author(s): Keri Lestari*, Ajeng Diantini, Melisa I. Barliana, Tri H. Achmad, Anas Subarnas, Mutakin, Rizky Abdulah, Ronny Lesmana, Jae K. Hwang.

Journal Name: The Natural Products Journal

Volume 9 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Nutmeg (Myristica fragrans Houtt) has the potential to control blood glucose and lipid levels. However, it contains safrole compounds, which are dangerous when humans consume them.

Objective: In this study, we eliminated safrole from nutmeg and investigated its antidiabetic and antidyslipidemic properties.

Methods: Nutmeg seeds were powdered, extracted with 90% ethanol, and chromatographed to remove the safrole. Safrole-free nutmeg extract was concentrated, and its antidiabetic and antidyslipidemic agents were tested in a type 2 diabetes mellitus rat model.

Results: The results showed that the blood glucose level decreased by 20% after 2 days of treatment, 30% after 4 days of treatment and 40% after 6 days of treatment with nutmeg extracts. The blood triglyceride level did not change in the first 2 days of treatment, and it decreased by 25% after 4 days of treatment and by another 25% after 6 days of treatment. Luciferase assay showed that safrole- free nutmeg increased the activities of PPAR α and γ in a dose-dependent manner, which marked the potential mechanism of lowering the triglyceride and glucose levels.

Conclusion: Results thus obtained are suggestive of the potential dual effect of safrole-free nutmeg extract on antidiabetic and antidyslipidemic management.

Keywords: Nutraceutical, nutmeg seed extract, antidiabetic, antidyslipidemic, PPARα/γ, diabetes mellitus.

[1]
Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract., 2010, 87(1), 4-14.
[2]
Abebe, S.M.; Berhane, Y.; Worku, A. Barriers to diabetes medication adherence in North West Ethiopia. Springerplus, 2014, 3, 195.
[3]
McCall, C. Country in Focus, Indonesia struggles to pay for the increase in diabetes. Lancet Diabetes Endocrinol., 2016, 4(8), 653-654.
[4]
Chen, S.C.; Tseng, C.H. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev. Diabet. Stud., 2013, 10(2-3), 88-100.
[5]
Donnelly, L.A.; Doney, A.S.; Morris, A.D.; Palmer, C.N.; Donnan, P.T. Long-term adherence to statin treatment in diabetes. Diabet. Med., 2008, 25(7), 850-855.
[6]
Alfian, S.D.; Sukandar, H.; Lestari, K.; Rizky, A. Medication adherence contributes to an improved quality of life in type 2 diabetes mellitus patients, A cross-sectional study. Diabetes Ther., 2016, 7(4), 755-764.
[7]
Han, K.L.; Choi, J.S.; Lee, J.Y.; Song, J.; Joe, M.K.; Jung, M.H.; Hwang, J.K. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes, 2008, 57(3), 737-745.
[8]
Widyowati, R.; Agil, M. Chemical constituents and bioactivities of several indonesian plants typically used in Jamu. Chem. Pharm. Bull. (Tokyo), 2018, 66(5), 506-518.
[9]
Yuniarti, T. Encyclopedia of Traditional Medicinal Plants; Yogyakarta Media Pressindo. , 2008.
[10]
Archer, A.W. Determination of safrole and myristicin in nutmeg and mace by high-performance liquid chromatography. J. Chromatogr. , 1988, 438(1), 117-121.
[11]
Qiu, Q.; Zhang, G.; Sun, X.; Liu, X. Study on chemical constituents of the essential oil from Myristica fragrans Houtt. by supercritical fluid extraction and steam distillation. Zhong Yao Cai, 2004, 27(11), 823-826.
[12]
Barceloux, D.G. Nutmeg (Myristica fragrans Houtt.). Dis. Mon., 2009, 55(6), 373-379.
[13]
Miller, J.A.; Miller, E.C. The metabolic activation and nucleic acid adducts of naturally-occurring carcinogens, recent results with ethyl carbamate and the spice flavors safrole and estragole. Br. J. Cancer, 1983, 48(1), 1-15.
[14]
Yang, A.H.; Zhang, L.; Zhi, D.X.; Liu, W.L.; Gao, X.; He, X. Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole. Xenobiotica, 2018, 48(11), 1164-1172.
[15]
Chien, K.J.; Yang, M.L.; Tsai, P.K.; Su, C.H.; Chen, C.H.; Horng, C.T.; Yeh, C.H.; Chen, W.Y.; Lin, M.L.; Chen, C.J.; Chian, C.Y.; Kuan, Y.H. Safrole induced cytotoxicity, DNA damage, and apoptosis in macrophages via reactive oxygen species generation and Akt phosphorylation. Environ. Toxicol. Pharmacol., 2018, 64, 94-100.
[16]
Rep, C. National Toxicology Program. Safrole, 2011, 12, 374-375.
[17]
Nair, A.B.; Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm., 2016, 7(2), 27-31.
[18]
Nair, A.; Morsy, M.A.; Jacob, S. Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. Drug Dev. Res., 2018.
[http://dx.doi.org/10.1002/ddr.21461]
[19]
Billington, E.O.; Grey, A.; Bolland, M.J. The effect of thiazolidinediones on bone mineral density and bone turnover, systematic review and meta-analysis. Diabetologia, 2015, 58(10), 2238-2246.
[20]
Tuccori, M.; Filion, K.B.; Yin, H.Yu. O.H.; Platt, R.W. Pioglitazone use and risk of bladder cancer, population based cohort study. BMJ, 2016, 352, i1541.
[21]
Patil, S.B.; Ghadyale, V.A.; Taklikar, S.S.; Kulkarni, C.R.; Arvindekar, A.U. Insulin secretagogue, alpha-glucosidase and antioxidant activity of some selected spices in streptozotocin-induced diabetic rats. Plant Foods Hum. Nutr., 2011, 66(1), 85-90.
[22]
Murakami, Y.; Shoji, M.; Hirata, A.; Tanaka, S.; Yokoe, I.; Fujisawa, S. Dehydrodiisoeugenol, an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages. Arch. Biochem. Biophys., 2005, 434(2), 326-332.
[23]
Lestari, K. Development of Nutmeg Seeds (Myristica fragrans Houtt.) as anti-hyperglycemic and anti-dyslipidemic with dual agonist effect on PPAR α / γ for management of Diabetes Mellitus Type 2; Bandung Universitas Padjadjaran. , 2010.
[24]
Feng, X.; Gao, X.; Jia, Y.; Xu, Y. PPAR-alpha agonist fenofibrate reduces insulin resistance in impaired glucose tolerance patients with hypertriglyceridemia, A cross-sectional study. Diabetes Ther., 2017, 8(2), 433-444.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 3
Year: 2019
Page: [248 - 253]
Pages: 6
DOI: 10.2174/2210315509666190206122849

Article Metrics

PDF: 14
HTML: 1